Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding

Br J Haematol. 2001 Dec;115(4):998-1001. doi: 10.1046/j.1365-2141.2001.03214.x.

Abstract

In an open non-randomized study, 10 patients with major bleeding and an Internationalized Normal Ratio (INR) greater than 14 were treated with 5 mg of intravenous vitamin K and 30 iu/kg of a single concentrate containing factors II, VII, IX and X (Beriplex P/N; Aventis Behring). The levels of these factors before and immediately after treatment were 4.7, 1.6, 8.5 and 1.1 iu/dl and 94, 30, 66 and 91 iu/dl respectively. The median INR before treatment was greater than 20 and, after treatment, 1.1. All patients had a satisfactory clinical response with immediate cessation of bleeding, and no thromboembolic complications occurred.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anticoagulants / adverse effects
  • Blood Coagulation Factors / therapeutic use*
  • Cohort Studies
  • Drug Combinations
  • Factor IX / therapeutic use
  • Factor VII / therapeutic use
  • Factor X / therapeutic use
  • Female
  • Hemorrhage / blood
  • Hemorrhage / drug therapy*
  • Humans
  • International Normalized Ratio
  • Male
  • Middle Aged
  • Prothrombin / therapeutic use
  • Thrombin / analysis
  • Vitamin K / therapeutic use*
  • Warfarin / adverse effects

Substances

  • Anticoagulants
  • Blood Coagulation Factors
  • Drug Combinations
  • Vitamin K
  • Warfarin
  • Factor VII
  • Prothrombin
  • Factor IX
  • Factor X
  • Thrombin